You are here: Industry Insights > PD-L1

News List

On sale with the unit price of CNY 12,375/bottle, Sugemalimab is planning to file for a third indication PharmaSources/Yi
January 24, 2022
Recently, Sugemalimab (trade name: Cejemly®), Stone Pharma PD-L1 monoclonal antibody, is on sale in China. It is reported that its public retail price is CNY 12,375/bottle (600mg/20ml) (tax included).
Cemiplimab Prolongs Survival in Recurrent Cervical Cancer drugs.com
February 10, 2022
For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab....
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B prnasia
January 18, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab)...
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors prnasia
January 10, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 prnasia
December 23, 2021
Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 in the United States.
First Patient Dosed in Australia in ATG-101 First-in-Human Trial prnasia
December 20, 2021
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics...
EC approves Merck’s Keytruda and chemotherapy combination for TNBC patients Pharmaceutical-Business-Review
October 28, 2021
The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients.
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China prnasia
October 22, 2021
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial...
Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Associat prnasia
October 13, 2021
Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB)...
Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005 prnasia
July 15, 2021
Transcenta Holding Limited announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005.

Previous page 1 2 3 4 5 Next page